BMEA vs BMY · $94.7M cap vs P/E 17, rev $48.19B
Biomea Fusion Inc (BMEA) versus Bristol-Myers Squibb Company (BMY) — a side-by-side from cached financials, not a winner call.
Biomea Fusion Inc (BMEA) is a biotechnology company listed on US.
Bristol-Myers Squibb Company (BMY) is a drug manufacturers - general company listed on US. It is led by Chris Boerner.
BMEA does not have a complete income-statement cache yet.
Latest reported BMY revenue for 2025-12-31 was $48.19B. Net income was $7.05B. Revenue was down 0.2% from 2024-12-31 to 2025-12-31. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
BMEA currently screens at market cap $94.7M. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
Not investment advice. Open the BMEA and BMY stock pages for the full models.
Not investment advice.